ArticleAlzheimer's & dementia (New York, N. Y.)2016

Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease.

Andrew Satlin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.